logo

For the Inventor, By the Inventor

Melbourne, Australia

Andrew Ewart Scott

This inventor holds 11 USPTO granted patents and 1 EPO patent. Top assignees: Ludwig Institute for Cancer Research Limited, Beijing University of Technology, Commonwealth Scientific and Industrial Research Organisation. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Ewart Scott. Retrieved from https://idiyas.com/inventor/andrew-ewart-scott

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 81.8


Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 60(Granted Patents)


Location History:

  • Parkville, AU (2010)
  • Heidelberg, AU (2015)
  • Melbourne, AU (2008 - 2016)
  • Kew East, AU (2010 - 2022)

Company Filing History:

goldMedal9 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal2 out of 389 
 
Beijing University of Technology
 patents
bronzeMedal2 out of 1,355 
 
Commonwealth Scientific and Industrial Research Organisation
 patents
4. 2 out of 8,578 
 
Massachusetts Institute of Technology
 patents
5. 1 out of 19 
 
Kalobios Pharmaceuticals, Inc.
 patents
6. 1 out of 618 
 
Memorial Sloan Kettering Cancer Center
 patents
7. 1 out of 2 
 
Paracrine Therapeutics Ab
 patents
8. 1 out of 45 
 
Telstra Corporation Limited
 patents
9. 1 out of 16,008 
 
University of California
 patents
where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 11352420 - Methods and compositions for PDGF-CC inhibition (2022-06-07),
2. 10023653 - Anti-metalloprotease antibody for diagnosis and treatment of cancers (2018-07-17),
3. 9283276 - Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof (2016-03-15),
4. 9241059 - Callee rejection information for rejected voice calls (2016-01-19),
5. 9023356 - Treatment method using EGFR antibodies and SRC inhibitors and related formulations (2015-05-05),
6. 8652473 - Antibodies to EGF receptor epitope peptides and uses thereof (2014-02-18),
7. 8637016 - EphA3 antibodies for the treatment of solid tumors (2014-01-28),
8. 7897743 - Humanized GM-CSF antibodies (2011-03-01),
9. 7767792 - Antibodies to EGF receptor epitope peptides (2010-08-03),
10. 7714113 - Fusion proteins of humanized g250 specific antibodies and uses thereof (2010-05-11),
11. 7381801 - Chimerized GM-CSF antibodies (2008-06-03),

Title: The Innovative Journey of Andrew Ewart Scott

Introduction: Andrew Ewart Scott, a pioneering inventor hailing from Melbourne, AU, has made significant contributions to the world of innovations and patents with his groundbreaking ideas and inventions.

Latest Patents: Andrew Ewart Scott holds several patents in various fields, including technology, healthcare, and sustainability. His most recent patents focus on renewable energy solutions and smart home technologies, showcasing his commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Andrew Ewart Scott has established himself as a leading figure in the innovation industry. His work has been recognized globally, earning him prestigious awards and accolades for his inventive spirit and dedication to pushing the boundaries of what is possible.

Collaborations: Throughout his career, Andrew Ewart Scott has collaborated with top researchers, engineers, and companies to bring his ideas to life. His ability to work effectively in multidisciplinary teams has led to the successful development and commercialization of several groundbreaking inventions.

Conclusion: In conclusion, Andrew Ewart Scott's passion for innovation and his relentless pursuit of excellence have cemented his legacy as a visionary inventor. His contributions to the field of patents and inventions continue to inspire future generations to think creatively and push the boundaries of what is possible in the world of technology and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…